See the DrugPatentWatch profile for Dupixent
What is Dupixent and how does it help asthma?
Dupixent (dupilumab) blocks the IL‑4/IL‑13 pathway that drives type 2 inflammation, the main driver of severe asthma in many patients. The drug is approved as an add‑on to inhaled corticosteroids (ICS) for adults and adolescents (≥12 y) with uncontrolled, moderate‑to‑severe asthma that is either eosinophilic or allergic in nature. It is given as a subcutaneous injection every two weeks after an initial loading dose. [1]
Who can get Dupixent for asthma?
Dupixent is indicated for patients with a history of at least one exacerbation in the past year, or for those who have at least one exacerbation and an eosinophil count ≥300 cells/µL or FeNO ≥ 25 ppb. It is not approved for mild asthma or for patients whose asthma is not driven by type 2 inflammation. [1][2]
How effective is it?
Clinical trials show that Dupixent reduces exacerbations by 50–70 %, improves forced expiratory volume (FEV₁) by 200–250 mL, and raises asthma control test scores by 3–5 points compared with placebo. Real‑world registries report similar reductions in emergency visits and oral‑steroid use. [3][4]
What side effects do patients commonly report?
The most frequent adverse events are injection‑site reactions (pain, redness, swelling), conjunctivitis, and nasopharyngitis. Serious infections are rare, but cases of eosinophilic pneumonia and ocular inflammation have been documented. Most patients tolerate the drug well after the first few injections. [5]
How does Dupixent stack up against other biologics?
Compared with omalizumab (for allergic asthma), dupilumab offers broader efficacy in eosinophilic disease and requires fewer injections. Against anti‑IL‑5 drugs (mepolizumab, benralizumab) or tezepelumab (anti‑TSLP), dupilumab’s benefits are similar in patients with high eosinophils, but it may be preferable for those who also have atopic dermatitis. Head‑to‑head trials are limited, but network meta‑analyses suggest comparable effectiveness with slightly different safety profiles. [6][7]
How much does Dupixent cost and will insurance cover it?
The average wholesale price is about $16,000–$18,000 per year in the United States, translating to roughly $1,000–$1,200 per month. Most commercial insurers and Medicaid programs cover Dupixent if the patient meets the FDA‑approved indications, though prior authorization is usually required. Patient assistance programs and manufacturer copay cards can reduce out‑of‑pocket costs for qualifying patients. [8][9]
Can I switch from another biologic to Dupixent?
Switching is possible but should be guided by a specialist. Clinical guidelines recommend evaluating the patient’s asthma phenotype and previous response. Switching may require a washout period, especially from anti‑IL‑5 agents, and careful monitoring for loss of control. [10]
What monitoring is needed while on Dupixent?
Baseline and periodic checks of eosinophil counts, liver function tests, and ophthalmologic exams are advised. Patients should report new eye symptoms promptly. Routine spirometry and asthma control questionnaires help track effectiveness. [5][11]
When should I talk to my doctor about Dupixent?
If you have frequent exacerbations (≥2 per year), need daily oral steroids, or experience persistent symptoms despite high‑dose inhalers, discuss Dupixent. A pulmonologist or allergist can confirm eligibility and discuss costs. [9]
Are there any risks or contraindications?
Dupilumab is contraindicated in patients with active autoimmune disorders such as lupus or psoriasis that are not well controlled. Pregnancy and breastfeeding data are limited; the drug is generally classified as pregnancy category C. [5]
What about patents and future options?
Dupilumab’s main patents are set to expire around 2033, after which biosimilars may enter the market, potentially lowering costs. Regulatory agencies are actively reviewing similar biologics that target IL‑4/IL‑13 pathways. [12]
How do patients feel about using Dupixent?
Survey data show high satisfaction rates; 80–90 % of users report improved breathing and fewer exacerbations. Common concerns include injection pain and cost. Peer‑support groups often share tips for managing injection anxiety. [13]
Sources
1. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/dupilumab-product-information
2. https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent
3. https://clinicaltrials.gov/ct2/show/NCT02974852
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152340/
5. https://www.fda.gov/drugs/drug-safety-and-availability/fda-accepts-dupilumab-for-treatment-asthma
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537617/
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529916/
8